Dr. Mohanram Narayanan, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 44
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 289
Licensed in Texas since 1990, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
TX license H7797 (first issued 1990; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor Scott & White Medical Center - Temple Temple, TX
- Baylor Scott & White Medical Center - Round Rock Round Rock, TX
- Baylor Scott & White Medical Center Hillcrest Waco, TX
- Baylor Scott & White Medical Center -Taylor Taylor, TX
Medical groups
- Scott and White Clinic (2,461 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 289
- Services billed
- 782
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 292 | 160 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 152 | 17 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 78 | 28 |
| Hemodialysis procedure with physician evaluation | 50 | 28 |
| New patient office or other outpatient visit, 60-74 minutes | 49 | 49 |
| Insertion of needle into vein for collection of blood sample | 19 | 12 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 14 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Temple, TX | 231 |
| Atorvastatin Calcium Other prescribers in Temple, TX | 219 |
| Allopurinol Other prescribers in Temple, TX | 181 |
| Losartan Potassium Other prescribers in Temple, TX | 138 |
| Amlodipine Besylate Other prescribers in Temple, TX | 131 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Temple, TX | 102 |
| Carvedilol Other prescribers in Temple, TX | 81 |
| Cinacalcet Hcl Other prescribers in Temple, TX | 76 |
| Jardiance (empagliflozin) Other prescribers in Temple, TX | 74 |
| Lisinopril Other prescribers in Temple, TX | 68 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 66 payments worth $29,603 in total to this clinician.
| Travere Therapeutics, Inc. | $13,292 |
|---|---|
| Otsuka America Pharmaceutical, Inc. | $8,920 |
| Lilly USA, LLC | $3,848 |
| Calliditas Therapeutics US Inc. | $2,715 |
| Novartis Pharmaceuticals Corporation | $284 |
| Amgen Inc. | $202 |
| Mallinckrodt Hospital Products Inc. | $87.88 |
| Ardelyx, Inc. | $70.77 |
| Consulting Fee | $13,651 |
|---|---|
| Speaking at a medical education program | $5,300 |
| Travel and Lodging | $4,622 |
| Compensation for services other than consulting (speaking, faculty) | $3,848 |
| Food and Beverage | $2,182 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. Mar 20, 2025 | Consulting Fee | $8,030 |
| Travere Therapeutics, Inc. Nov 7, 2025 | Consulting Fee Filspari · Kidney Disease | $3,000 |
| Travere Therapeutics, Inc. Jun 20, 2025 | Speaking at a medical education program Filspari · Kidney Disease | $3,000 |
| Calliditas Therapeutics US Inc. Apr 28, 2025 | Consulting Fee TARPEYO · NEPHROLOGY | $2,621 |
| Lilly USA, LLC Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,568 |
| Travere Therapeutics, Inc. Jun 13, 2025 | Speaking at a medical education program Filspari · Kidney Disease | $1,500 |
| Lilly USA, LLC Sep 15, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,140 |
| Lilly USA, LLC Jul 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,140 |
| Travere Therapeutics, Inc. Jun 5, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to Lubbock, TX · in-kind | $984 |
| Travere Therapeutics, Inc. Oct 24, 2025 | Travel and Lodging travel to Minneapolis, MN · in-kind | $976 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Nov 7, 2025 | Consulting Fee Filspari · Kidney Disease | $3,000 |
| Travere Therapeutics, Inc. Oct 30, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to College Station, TX · in-kind | $698 |
| Travere Therapeutics, Inc. Oct 27, 2025 | Travel and Lodging travel to Minneapolis, MN · in-kind | $91.87 |
| Travere Therapeutics, Inc. Oct 24, 2025 | Travel and Lodging travel to Minneapolis, MN · in-kind | $976 |
| Travere Therapeutics, Inc. Oct 15, 2025 | Speaking at a medical education program Filspari · Kidney Disease | $800 |
| Travere Therapeutics, Inc. Oct 11, 2025 | Travel and Lodging travel to Minneapolis, MN · in-kind | $240 |
| Lilly USA, LLC Sep 15, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,140 |
| Lilly USA, LLC Jul 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,140 |
| Travere Therapeutics, Inc. Jun 20, 2025 | Speaking at a medical education program Filspari · Kidney Disease | $3,000 |
| Travere Therapeutics, Inc. Jun 13, 2025 | Speaking at a medical education program Filspari · Kidney Disease | $1,500 |
| Travere Therapeutics, Inc. Jun 5, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to Lubbock, TX · in-kind | $984 |
| Travere Therapeutics, Inc. Jun 5, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to Lubbock, TX · in-kind | $377 |
| Travere Therapeutics, Inc. Jun 5, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to Lubbock, TX · in-kind | $238 |
| Travere Therapeutics, Inc. Jun 5, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to Lubbock, TX · in-kind | $230 |
| Travere Therapeutics, Inc. Jun 5, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to Lubbock, TX · in-kind | $207 |
| Travere Therapeutics, Inc. Jun 5, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to Lubbock, TX · in-kind | $164 |
| Travere Therapeutics, Inc. Jun 5, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to Lubbock, TX · in-kind | $18.00 |
| Calliditas Therapeutics US Inc. Apr 28, 2025 | Consulting Fee TARPEYO · NEPHROLOGY | $2,621 |
| Otsuka America Pharmaceutical, Inc. Mar 20, 2025 | Consulting Fee | $8,030 |
| Otsuka America Pharmaceutical, Inc. Mar 20, 2025 | Travel and Lodging travel to ROUND ROCK, TX | $52.08 |
| Otsuka America Pharmaceutical, Inc. Mar 20, 2025 | Travel and Lodging travel to AUSTIN, TX | $34.19 |
| Otsuka America Pharmaceutical, Inc. Mar 20, 2025 | Travel and Lodging travel to ROUND ROCK, TX | $5.60 |
| Lilly USA, LLC Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,568 |
| Otsuka America Pharmaceutical, Inc. Feb 9, 2025 | Travel and Lodging travel to DFW AIRPORT, TX · in-kind | $304 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $859,177 in research payments for these studies, mostly to the institutions running them.
- A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephriti…
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Amgen Inc. - A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated - LUPKYNIS Registry Study
Aurinia Pharma U.S., Inc. - A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus
Novartis Pharmaceuticals Corporation - A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult aHUS Patients Who Are Naive to Complement Inhibitor Therapy
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.